The JAK2 inhibitors did not substantially up‐ or down‐regulate the expression of other target antigens, such as CD26, CD44, CD47, CD52, CD97, CD135, CD184, CD206, CD243, or EPOR on MPN NSC (Figure 4). The gene discussed is CXCR4; the disease is myeloproliferative neoplasm.